10-Mar-2025 9:21 AM CST - Business Wire Genmab Announces Johnson & Johnson Decision Regarding HexaBody-CD38 Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmabs rigorous portfolio prioritization, Genmab will not pursue f
Latest GMAB Trades by Congress Members
16-JAN-2025 - Josh Gottheimer, NJ (District 5) purchased between $1,001 and $15,000.
10-Mar-2025 9:21 AM CST - Business Wire Genmab Announces Johnson & Johnson Decision Regarding HexaBody-CD38 Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmabs rigorous portfolio prioritization, Genmab will not pursue f
